Ionis Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (18)

Latest Posts

About This Stock More About This Stock
Akcea, Ionis Slide After FDA Document Highlights Volanesorsen 'Safety Concerns'
Article By: The Fly
Tuesday, May 8, 2018 12:51 PM EDT
Shares of Ionis Pharmaceuticals and its majority-owned spinout Akcea Therapeutics are sliding after the Food and Drug Administration posted its briefing document ahead of Thursday's meeting to discuss the latter's volanesorsen.
In this article: IONS Also: AKCA, ALNY
Akcea Falls After FDA Panel Discusses 'Safety Concerns' Of Volanesorsen
Article By: The Fly
Tuesday, May 8, 2018 9:37 AM EDT
Akcea Therapeutics and its controlling holder Ionis Pharmaceuticals are moving lower after an FDA panel posted its briefing document ahead of Thursday's meeting to discuss Akcea's volanesorsen.
In this article: AKCA, IONS
4 Scorching Hot Momentum Stocks To Beat The Market
Article By: Zacks Investment Research
Tuesday, October 31, 2017 1:25 AM EDT
Momentum is basically the tendency of winning stocks to keep winning and losing stocks to keep losing.
In this article: GBX, SKX, IONS, OSB
Week In Review: Tianjin CanSino Closes $65 Million Round For Vaccine Portfolio
Article By: ChinaBio® Today
Saturday, April 22, 2017 3:40 PM EDT
Tianjin CanSino Biologics, a vaccine developer, raised $65 Million in its latest funding round. Currently, CanSino is testing four products in Phase I to III clinical trials, conducted in North America, Africa and China respectively.
In this article: MRK, PFE, CELG, IONS, BGNE
Novartis-Backed Ionis Subsidiary Akcea Maps A $100M IPO As It Steers A Lead Drug To Regulators
Article By: Lorimer Wilson
Monday, March 27, 2017 6:16 PM EDT
Ionis Pharmaceuticals, Inc. subsidiary Akcea — a specialist in lipid disorders — is shooting for a $100 million IPO, with Novartis coming in to support the move with an extra $50 million to purchase a growing equity stake.
In this article: NVS, IONS


Latest Tweets for $IONS

No tweets yet!